A Phase 2 Study of Continuous Subcutaneous Hydrocortisone Infusion in Adults With Congenital Adrenal Hyperplasia
Open accessThe DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Abstract
CONTEXT: Classic congenital adrenal hyperplasia (CAH) management remains challenging, given that supraphysiologic glucocorticoid doses are often needed to optimally suppress the ACTH-driven adrenal androgen overproduction. OBJECTIVE: This study sought to approximate physiologic cortisol secretion via continuous subcutaneous hydrocortisone infusion (CSHI) and evaluate the safety and efficacy of CSHI in patients with difficult-to-treat CAH. DESIGN: Eight adult patients with classic CAH participated in a single-center open-label phase I-II study comparing CSHI to conventional oral glucocorticoid treatment. All patients had elevated adrenal steroids and one or more comorbidities at study entry. Assessment while receiving conventional therapy at baseline and 6 months following CSHI included: 24-hour hormonal sampling, metabolic and radiologic evaluation, health-related quality-of-life (HRQoL), and fatigue questionnaires. MAIN OUTCOME MEASURES: The ability of CSHI to approximate physiologic cortisol secretion and the percent of patients with 0700-hour 17-hydroxyprogesterone (17-OHP) ≤1200 ng/dL was measured. RESULTS: CSHI approximated physiologic cortisol secretion. Compared with baseline, 6 months of CSHI resulted in decreased 0700-hour and 24-hour area under the curve 17-OHP, androstenedione, ACTH, and progesterone, increased osteocalcin, c-telopeptide and lean mass, and improved HRQoL (and SF-36 Vitality Score), and fatigue. One of three amenorrheic women resumed menses. One man had reduction of testicular adrenal rest tissue. CONCLUSIONS: CSHI is a safe and well-tolerated modality of cortisol replacement that effectively approximates physiologic cortisol secretion in patients with classic CAH poorly controlled on conventional therapy. Improved adrenal steroid control and positive effects on HRQoL suggest that CSHI should be considered a treatment option for classic CAH. The long-term effect on established comorbidities requires further study.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Continuous subcutaneous hydrocortisone infusion (CSHI) that approximates circadian cortisol secretion was previously shown to improve disease control in patients with 21OHD poorly controlled with OG therapy based on the traditional biomarkers 17OHP and A4 (7).”
In the citing paper
“Infants prenatally exposed to betamethasone have altered responses of the HPA axis and a higher incidence of mental and behavioral disorders (490,491).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [491]
In the citing paper
“and showed improved quality-of-life and fatigue in 8 patients with classic 21-OH deficiency.142”
From Congenital adrenal hyperplasia (2017) · cites this paper as [142]
In the citing paper
“Long-standing comorbidities, such as insulin resistance and TART, remained mostly unchanged by 6 months”
From Congenital adrenal hyperplasia (2017) · cites this paper as [142]
In the citing paper
“Continuous subcutaneous hydrocortisone infusion via an insulin pump mimicking cortisol circadian rhythm, has similarly shown adequate ACTH suppression with lower total hydrocortisone dose compared to conventional treatment, 139-142”
From Congenital adrenal hyperplasia (2017) · cites this paper as [142]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 1×
“5 (18, 19)], osteopenia or osteoporosis (BMD T-score –1), or glucocorticoid-related gastrointestinal (GI) side effects.”
BackgroundOverview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project
Ware, J. E., & Gandek, B. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00081-x · Cited by 2,605 · cited 1×
“SF-36 score was calculated using the SF-36 OptumInsight software which provides norm-based scores and applies a linear T-score transformation (mean 50, SD 10) (22, 26).”
MethodSpeiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468 · cited 2×
“(1) Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA 20892; (2) National Institutes of Health Clinical Center, Bethesda MD, USA 20892”
BackgroundSelf-citationUltrasound scanning in the detection of hepatic fibrosis and steatosis.
Saverymuttu, S. H., Joseph, A. E., & Maxwell, J. D. (1986) · BMJ · doi:10.1136/bmj.292.6512.13 · Cited by 853 · cited 1×
“0 kg/m(2)], fatty liver disease [AST to ALT ratio 1 (16) and/or steatosis per liver ultrasound (17)], low insulin sensitivity [Homeostasis Model Assessment Insulin Resistance (HOMA-IR) 2.”
BackgroundCongenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669
Self-citationHealth status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients
Arlt, W., Willis, D. S., Wild, S. H., Krone, N., Doherty, E. J., Hahner, S., Han, T. S., Carroll, P. V., Conway, G. S., Rees, D. A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0917 · Cited by 506 · cited 2×
“(1) Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA 20892; (2) National Institutes of Health Clinical Center, Bethesda MD, USA 20892”
BackgroundAscaso, J. F., Pardo, S., Real, J. T., Lorente, R. I., Priego, A., & Carmena, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3320 · Cited by 490 · cited 1×
“5 (18, 19)], osteopenia or osteoporosis (BMD T-score –1), or glucocorticoid-related gastrointestinal (GI) side effects.”
BackgroundSorbi, D. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00061-1 · Cited by 466 · cited 1×
“0 kg/m(2)], fatty liver disease [AST to ALT ratio 1 (16) and/or steatosis per liver ultrasound (17)], low insulin sensitivity [Homeostasis Model Assessment Insulin Resistance (HOMA-IR) 2.”
BackgroundComparison of self-reported fatigue in rheumatoid arthritis and controls.
Bl, B. (1995) · PubMed · Cited by 355
Modified-release hydrocortisone to provide circadian cortisol profiles
Debono, M., Ghobadi, C., Rostami-Hodjegan, A., Huatan, H., Campbell, M. J., Newell-Price, J., Darzy, K., Merke, D. P., Arlt, W., & Ross, R. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2380 · Cited by 322 · cited 5×
“Rates were established to achieve peak and trough concentrations within the normal circadian cortisol range based on an estimate of the mean in healthy controls (6) and by using the formula [Infusion Rate (mg/24hrs) clearance (mL/24hr) x target cortisol concentration (mg/mL)].”
BackgroundMethodResultInfluentialSelf-citation
Cited by
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Self-citationCongenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669
Self-citationCongenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Self-citationCongenital adrenal hyperplasia due to 21-hydroxylase deficiency
Merke, D. P., & Auchus, R. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1909786 · Cited by 341
Self-citationHahner, S., Ross, R. J., Arlt, W., Bancos, I., Burger-Stritt, S., Torpy, D. J., Husebye, E. S., & Quinkler, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00252-7 · Cited by 223
Congenital adrenal hyperplasia
Auer, M. K., Nordenström, A., Lajic, S., & Reisch, N. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01330-7 · Cited by 215
Carmina, E., Dewailly, D., Escobar-Morreale, H. F., Kelestimur, F., Moran, C., Oberfield, S., Witchel, S. F., & Azziz, R. (2017) · Human Reproduction Update · doi:10.1093/humupd/dmx014 · Cited by 201
“…antagonists are being investigated in adult females with CAH (Auchus et al., 2015) and subcutaneous hydrocortisone therapy has been tried in a limited number of individuals with CAH who have a rapid clearance of cortisol or those who cannot tolerate oral glucocorticoid therapy (Nella et al., 2016).”
Nordenström, A., & Falhammar, H. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0712 · Cited by 158
Epidemiology, pathogenesis, and diagnosis of Addison’s disease in adults
Betterle, C., Presotto, F., & Furmaniak, J. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01079-6 · Cited by 161
Management challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
Self-citationModified-Release Hydrocortisone in Congenital Adrenal Hyperplasia
Merke, D. P., Mallappa, A., Arlt, W., Brac de la Perriere, A., Lindén Hirschberg, A., Juul, A., Newell-Price, J., Perry, C. G., Prete, A., Rees, D. A., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab051 · Cited by 109
“QoL has been shown to improve when using a pump to deliver subcutaneous diurnal hydrocortisone infusion to 21-OHD-CAH patients with poor control and QoL at baseline (17); however, QoL in 21-OHD-CAH has variably been reported as either impaired or normal (44).”
BackgroundMethodSelf-citationTurcu, A. F., Mallappa, A., Elman, M. S., Avila, N. A., Marko, J., Rao, H., Tsodikov, A., Auchus, R. J., & Merke, D. P. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3989 · Cited by 107
“For the one patient receiving continuous hydrocortisone infusion, the GCE was the total daily hydrocortisone dose (21).”
Self-citationMazziotti, G., Formenti, A. M., Frara, S., Roca, E., Mortini, P., Berruti, A., & Giustina, A. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0154 · Cited by 96
El-Maouche, D., Hargreaves, C. J., Sinaii, N., Mallappa, A., Veeraraghavan, P., & Merke, D. P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00208 · Cited by 93
“2340 El-Maouche et al Assessment of Acute Illnesses in Patients With CAH J Clin Endocrinol Metab, June 2018, 103(6):2336–2345”
BackgroundSelf-citationWhittle, E., & Falhammar, H. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00136 · Cited by 87
“[12] assessed changes in metabolic indices and found that weight increased with CSHI compared with individuals’ baseline glucocorticoid regimens, whereas other indices did not change (including HOMA-IR; levels of C-peptide, leptin, C-reactive protein, and lipids; and waist-to-hip ratio).”
BackgroundResultInfluentialMonogenic disorders of adrenal steroidogenesis
Baranowski, E. S., Arlt, W., & Idkowiak, J. (2018) · Hormone Research in Paediatrics · doi:10.1159/000488034 · Cited by 79
Primary adrenal insufficiency in children: Diagnosis and management
Kırkgöz, T., & Güran, T. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.05.010 · Cited by 90
Central adrenal insufficiency in children and adolescents
Patti, G., Guzzeti, C., Di Iorgi, N., Maria Allegri, A. E., Napoli, F., Loche, S., & Maghnie, M. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.03.012 · Cited by 75
Human studies on hypothalamo-pituitary-adrenal (HPA) axis
Liyanarachchi, K., Ross, R. J. M., & Debono, M. (2017) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2017.10.011 · Cited by 98
Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia
Auchus, R. J., Hamidi, O., Pivonello, R., Bancos, I., Russo, G., Witchel, S. F., Isidori, A. M., Rodien, P., Srirangalingam, U., Kiefer, F. W., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404656 · Cited by 79
Self-citationAbiraterone acetate treatment lowers 11-oxygenated androgens
Wright, C., O’Day, P., Alyamani, M., Sharifi, N., & Auchus, R. J. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0905 · Cited by 68
“The 11oxygenated androgens are now recognized as the major androgens in patients with 21OHD (17), and new strategies to lower A4 and T (14, 24-26) must also reduce 11-oxygenated androgens, as we now show for AA.”
BackgroundPediatric Adrenal Insufficiency: Diagnosis, Management, and New Therapies
Bowden, S. A., & Henry, R. (2018) · International Journal of Pediatrics · doi:10.1155/2018/1739831 · Cited by 60
Auchus, R. J., Sarafoglou, K., Fechner, P. Y., Vogiatzi, M. G., Imel, E. A., Davis, S. M., Giri, N., Sturgeon, J., Roberts, E., Chan, J. L., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab749 · Cited by 55
Bachelot, A., Grouthier, V., Courtillot, C., Dulon, J., & Touraine, P. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0888 · Cited by 57
The Adrenal Cortex and its Disorders
Miller, W. L. (2009) · Brook's Clinical Pediatric Endocrinology · doi:10.1002/9781444316728.ch13 · Cited by 50
Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia
Prete, A., Auchus, R. J., & Ross, R. J. (2022) · White Rose Research Online (University of Leeds, The University of Sheffield, University of York) · Cited by 46
Mallappa, A., Nella, A. A., Sinaii, N., Rao, H., Gounden, V., Perritt, A. F., Kumar, P., Ling, A., Liu, C., Soldin, S. J., et al. (2018) · Clinical Endocrinology · doi:10.1111/cen.13813 · Cited by 45
Self-citationQuality of life in patients with adrenal disease: A systematic review
Ho, W., & Druce, M. (2018) · Clinical Endocrinology · doi:10.1111/cen.13719 · Cited by 44
Kalafatakis, K., Russell, G. M., Ferguson, S. G., Grabski, M., Harmer, C. J., Munafo, M. R., Marchant, N., Wilson, A., Brooks, J. C. W., Thakrar, J., et al. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.105096 · Cited by 38
A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia
El-Maouche, D., Merke, D. P., Vogiatzi, M. G., Chang, A. Y., Turcu, A. F., Joyal, E. G., Lin, V. H., Weintraub, L., Plaunt, M. R., Mohideen, P., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa381 · Cited by 34
Self-citationMelin, J., Parra-Guillen, Z. P., Michelet, R., Truong, T., Huisinga, W., Hartung, N., Hindmarsh, P., & Kloft, C. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa071 · Cited by 34
Auer, M. K., Paizoni, L., Hofbauer, L. C., Rauner, M., Chen, Y., Schmidt, H., Huebner, A., Bidlingmaier, M., & Reisch, N. (2020) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2020.105734 · Cited by 33
“Factors reported to affect bone health in CAH are particularly cumulative GC (12-15) and androgen exposure (11, 12).”
Latest Insights on the Etiology and Management of Primary Adrenal Insufficiency in Children
Güran, T. (2018) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.2017.s002 · Cited by 34
“Continuous subcutaneous hydrocortisone infusion (CSHI) via a pump, similar to an insulin pump, is superior in achieving a better cortisol secretion profile and lowering ACTH concentrations in non-CAH PAI and in lowering serum androgens in CAH (41,42).”
BackgroundNovel treatments for congenital adrenal hyperplasia
Schröder, M. A. M., & der Grinten, H. L. C. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09717-w · Cited by 34
“Yet, improved QoL has not been reported by every study assessing CSHI for patients with adrenal insufficiency.”
BackgroundInfluentialMECHANISMS IN ENDOCRINOLOGY: Does circadian and ultradian glucocorticoid exposure affect the brain?
Kalafatakis, K., Russell, G. M., & Lightman, S. L. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0853 · Cited by 35
Health-related quality of life in children with congenital adrenal hyperplasia
Halper, A., Hooke, M. C., Gonzalez‐Bolanos, M. T., Vanderburg, N., Tran, T. N., Torkelson, J. L., & Sarafoglou, K. (2017) · Health and Quality of Life Outcomes · doi:10.1186/s12955-017-0769-7 · Cited by 33
“Circadian hydrocortisone delivery has been shown to improve QoL in adults with adrenal insufficiency and CAH [15, 16].”
BackgroundFuture Directions for Adrenal Insufficiency: Cellular Transplantation and Genetic Therapies
Graves, L. E., Torpy, D. J., Coates, P. T., Alexander, I. E., Bornstein, S. R., & Clarke, B. M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac751 · Cited by 24
Turcu, A. F., Mallappa, A., Nella, A. A., Chen, X., Zhao, L., Nanba, A. T., Byrd, J. B., Auchus, R. J., & Merke, D. P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.751191 · Cited by 20
“Plasma ACTH was analyzed at the NIH Clinical Center, Bethesda, Maryland by chemiluminescent immunoassay on Siemens Immulite 200 XPi analyzer (7).”
BackgroundMethodSelf-citationAdrenal morphology and associated comorbidities in congenital adrenal hyperplasia
El‐Maouche, D., Hannah‐Shmouni, F., Mallappa, A., Hargreaves, C. J., Avila, N. A., & Merke, D. P. (2019) · Clinical Endocrinology · doi:10.1111/cen.13996 · Cited by 20
Self-citationMallappa, A., Nella, A. A., Kumar, P., Brooks, K. M., Perritt, A. F., Ling, A., Liu, C.-Y., & Merke, D. P. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00215 · Cited by 16
“Circadian cortisol replacement with a modified-release form of oral hydrocortisone (Chronocort; Diurnal, Cardiff, United Kingdom) and continuous subcutaneous hydrocortisone infusion (CSHI) improve control of adrenal androgens using similar or lower glucocorticoid doses than conventional glucocorticoid formulations [2,…”
BackgroundMethodSelf-citationSarafoglou, K., & Auchus, R. J. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae759 · Cited by 22
“…a phase 2 study in 8 adults with 21OHD who had elevated adrenal steroids (17OHP > 1200 ng/dL and/or A4 above normal range) and ≥ 1 disease-or glucocorticoid-related co-morbidities, treatment with CSHI was shown to achieve a cortisol profile similar to physiologic cortisol secretion (Table 1) (30 ).”
Emerging medical therapies for congenital adrenal hyperplasia
Speiser, P. (2019) · F1000Research · doi:10.12688/f1000research.17778.1 · Cited by 17
The Adrenal Cortex and Its Disorders
Hughes, C. R., Man, E., & Achermann, J. C. (2019) · Wiley eBooks · doi:10.1002/9781119152712.ch9 · Cited by 19
Current and future treatment options for adrenal insufficiency
Arshad, M. F., & Debono, M. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000637 · Cited by 13
“Subcutaneous hydrocortisone infusion treatment may have a role to play in AI, especially in those with gastric issues or in CAH when difficult to treat [47].”
BackgroundClassic congenital adrenal hyperplasia
Nermoen, I., Husebye, E. S., Myhre, A. G., & Løvås, K. (2017) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.16.0376 · Cited by 15
Graves, L. E., van Dijk, E. B., Zhu, E., Koyyalamudi, S. R., Wotton, T., Sung, D., Srinivasan, S., Ginn, S. L., & Alexander, I. E. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101232 · Cited by 15
“9 As current standard management is imperfect, alternative and adjunctive treatment options have been explored, including subcutaneous hydrocortisone pumps 10,11 and modi fi ed-release once-daily hydrocortisone.”
BackgroundManagement of congenital adrenal hyperplasia: beyond conventional glucocorticoid therapy
Khattab, A., & Marshall, I. H. (2019) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000780 · Cited by 14
Mortensen, M. L., Ørnstrup, M. J., & Gravholt, C. H. (2023) · International Journal of Endocrinology · doi:10.1155/2023/5315059 · Cited by 13
“Nella et al. [23] compared CSHI to conventional OHC treatment in 8 patients with congenital adrenal hyperplasia.”
BackgroundCongenital adrenal hyperplasia: New biomarkers and adult treatments
Dreves, B., Reznik, Y., & Tabarin, A. (2023) · Annales d Endocrinologie · doi:10.1016/j.ando.2023.01.008 · Cited by 15
Novel agents to treat adrenal insufficiency: findings of preclinical and early clinical trials
Peel, A., Rushworth, R. L., & Torpy, D. J. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2311207 · Cited by 8
“Serum ACTH [55,57,58], nocturnal glycemia [55], and 17-hydroxyprogesterone (in CAH) [58] were found to improve with short-term use, although quality of life improvements remains inconclusive [56,58] and long-term effects are unknown.”
BackgroundGenome editing in the adrenal gland: a novel strategy for treating congenital adrenal hyperplasia
van Dijk, E. B., Ginn, S. L., Alexander, I. E., & Graves, L. E. (2024) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2024.00011 · Cited by 8
Nouveautés dans l’hyperplasie congénitale des surrénales
Dumeige, L., Bouvattier, C. M., & Lombès, M. (2017) · Annales d Endocrinologie · doi:10.1016/s0003-4266(17)30922-8 · Cited by 8
Auchus, R. J., Courtillot, C., Dobs, A. S., El‐Maouche, D., Falhammar, H., Lacroix, A., Farrar, M., O’Donoghue, C., Anatchkova, M., Cutts, K. N., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1005963 · Cited by 9
“Median (range) 65 (10-96) 3 (2-20) 10 (5-80) 10 (5-80) 25”
Emerging treatment for congenital adrenal hyperplasia
White, P. C. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000723 · Cited by 8
“Continuous subcutaneous delivery of hydrocortisone (HC) using an insulin pump can closely mimic physiologic cortisol secretion patterns [18] and thus dampen the morning surge in ACTH and adrenal androgens [19 & ].”
BackgroundA review of menstrual sex education and management in women with congenital adrenal hyperplasia
Sanders, C. D., Usipuik, M., Amyot, E., Koopmans, E., Hall, J., Crawford, L., Todd, N. J., & Jones, T. M. (2021) · Sex Education · doi:10.1080/14681811.2021.1938524 · Cited by 6
“…2010; Böttcher, Dörr, and Wildt 2014; Einaudi et al. 2011; Gleeson et al. 2013; Gupta et al. 2006; Holmes-Walker et al. 1995; Nermoen et al. 2010; Moran et al. 2000; Völkl et al. 2011), while two studies were cross-sectional (Bachelot et al. 2015) and single-centre open-label (Nella et al. 2016).”
Flokas, M. E., Yang, L., Middleton, K. R., Kollender, S., Parker, M., Sukin, C., Persky, R., & Merke, D. P. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae309 · Cited by 6
Self-citationRoshan, D., Yadav, J., Kumar, R., Malhi, P., Sharma, A., & Dayal, D. (2021) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2021.109269 · Cited by 6
“Parental education was associated with lower parent-reported scores in some domains, which can be explained by the fact that the more educated the parents, the more informed and worried they would be regarding the children’s future, reflecting in their perception of child’s QoL [2, 23, 24].”
BackgroundVarlamov, E. V., & Fleseriu, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99899-4.00019-6 · Cited by 6
The Current Treatment Landscape for Congenital Adrenal Hyperplasia
Tonge, J. J., Bacila, I. A., & Krone, N. P. (2025) · Drugs · doi:10.1007/s40265-025-02216-7 · Cited by 4
Kyle, C. J., Boyle, L. D., Nixon, M., Homer, N. Z. M., Simpson, J., Rutter, A., Ramage, L. E., Kelman, A., Freel, E. M., Andrew, R., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae144 · Cited by 4
Stachanow, V., Neumann, U., Blankenstein, O., Alder‐Baerens, N., Bindellini, D., Hindmarsh, P. C., Ross, R. J. M., Whitaker, M. J., Melin, J., Huisinga, W., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16030464 · Cited by 3
“The PK/PD model captured the known mechanism of administered hydrocortisone inhibiting 17-OHP biosynthesis via the suppression of the HPA-axis by a negative feedback mechanism [1,2,12].”
BackgroundEndocrine Disturbances Affecting Reproduction
Chang, A. Y., & Auchus, R. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47912-7.00024-x · Cited by 5
Exploration of the potential of genomic editing in the treatment of congenital adrenal hyperplasia
Graves, L. E., Christina, S., Mullany, K., Alexander, I. E., & Falhammar, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1719376 · Cited by 2
Usipuik, M., Sanders, C. D., Amyot, E., Banner, D., & Jones, T. M. (2022) · The Canadian Journal of Human Sexuality · doi:10.3138/cjhs.2021-0043 · Cited by 2
Continuous subcutaneous hydrocortisone infusion causing refractory hypokalemia
Alghamdi, A. A., Aqeeli, M. O., & Aljehani, F. (2025) · Journal of Clinical and Translational Endocrinology Case Reports · doi:10.1016/j.jecr.2025.100188 · Cited by 2
The potential role of bone-derived factor ucOCN in the anti-depressive effects of exercise
Xianghe, C., Li, W., Liu, B., & Yin, R. (2021) · Advances in Psychological Science · doi:10.3724/sp.j.1042.2022.00375 · Cited by 2
Neues beim Adrenogenitalen Syndrom
Reisch, N. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0042-117270 · Cited by 3
“[5] Nella AA, Mallappa A, Perritt AF et al.”
InfluentialSchröder, M. A. M., van Herwaarden, A. E., Span, P. N., van den Akker, E. L. T., Bocca, G., Hannema, S. E., van der Kamp, H. J., Kort, S. W. K. D., Mooij, C. F., Schott, D. A., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab826 · Cited by 22
Advances in pharmacological treatment for congenital adrenal hyperplasia
Graves, L. E., & Falhammar, H. (2026) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001583 · Cited by 2
Case 1-2020: An 11-Year-Old Boy with Vomiting and Weight Loss
Fasano, A., Leonard, M. M., Mitchell, D. M., & Eng, G. M. (2020) · New England Journal of Medicine · doi:10.1056/nejmcpc1913469 · Cited by 1
Neue Behandlungsstrategien bei adrenogenitalem Syndrom/21‑Hydroxylase-Mangel
Riedl, S. (2022) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-022-00159-y · Cited by 1
Steroid Replacement in Adrenal Insufficiency
Blair, J., Debono, M., & Ross, R. J. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64307-6 · Cited by 1
Insuffisance surrénalienne secondaire : actualités diagnostiques et thérapeutiques
Vinolas, H., Lombès, M., & Tabarin, A. (2019) · Annales d Endocrinologie · doi:10.1016/s0003-4266(19)30111-8
Infusione sottocutanea continua di idrocortisone nella terapia dell’insufficienza corticosurrenalica
Gizzi, C., & Falorni, A. (2020) · L Endocrinologo · doi:10.1007/s40619-020-00679-2
Betterle, C., Presotto, F., & Zanchetta, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00042-7
Management of Adult Patients With Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
Grouthier, V., Dulon, J., Bachelot, A., & Touraine, P. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.66140-8
Honour, J. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818124-9.00004-8
Hydrocortisone Pump Therapy to Mimic the Circadian Rhythm
Hindmarsh, P. C., & Geertsma, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-824548-4.00022-x
Betterle, C., Sabbadin, C., & Presotto, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00056-4
Management of adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Grouthier, V., Dulon, J., Bachelot, A., & Touraine, P. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00132-1
Steroid replacement in adrenal insufficiency
Blair, J., Debono, M., & Ross, R. J. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00147-3
Congenital Adrenal Hyperplasia
Witchel, S. F., Oberfield, S. E., Fisher, A. S., & Trapp, C. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-66296-6_11
Hyperplasie congénitale des surrénales : formes précoces
Levaillant, L., Bouhours‐Nouet, N., Rouleau, S., Amsellem‐Jager, J., Donzeau, A., Briet, C., & Coutant, R. (2025) · EMC - Pédiatrie - Maladies infectieuses · doi:10.1016/s1637-5017(25)85172-x
Hiperplasia suprarrenal congénita: formas precoces
Levaillant, L., Bouhours-Nouet, N., Rouleau, S., Amsellem-Jager, J., Donzeau, A., Briet, C., & Coutant, R. (2025) · EMC - Pediatría · doi:10.1016/s1245-1789(25)51124-1
de la Perrière, A. B., & Martinerie, L. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.01.004
Nokoff, N., Fechner, P. Y., Kim, M. S., Marshall, I. H., Merke, D. P., Sarafoglou, K., Hartzell, A. L., Lin, V. H., & Thornton, P. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag192
Self-citationPharmacotherapeutic strategies for the management of congenital adrenal hyperplasia
Goai, W. H., & Torpy, D. J. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2695099
The evolution of new approaches to the treatment of congenital adrenal hyperplasia
Merke, D. P., & Auchus, R. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag033
Self-citationSzklarz, M., Wołos-Kłosowicz, K., Szulc, J., Górny, J. M., & Matuszewski, W. (2026) · Middle East Fertility Society Journal · doi:10.1186/s43043-026-00364-8
“A 6-month phase II study investigated this form of replacement in eight patients with 21OHD-CAH who had failed to achieve adequate disease control [117].”
Metadata
- Authors
- Nella, A. A., Mallappa, A., Perritt, A. F., Gounden, V., Kumar, P., Sinaii, N., Daley, L.-A., Ling, A., Liu, C.-Y., Soldin, S. J., & Merke, D. P.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Nella, Aikaterini A.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-12
- Volume
- 101
- Issue
- 12
- Pages
- 4690-4698
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC5155681
- OpenAlex
- W2524670571
- Cited by
- 91
- References
- 30
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 12 · 2023: 5 · 2022: 11 · 2021: 10 · 2020: 8 · 2019: 9 · 2018: 13 · 2017: 11
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- congenital adrenal hyperplasia, cortisol replacement therapy, 17-hydroxyprogesterone, ACTH, health-related quality of life, fatigue, bone mineral density, amenorrhea, adults
- MeSH terms
- Adrenal Hyperplasia, Congenital, Adult, Female, Glucocorticoids, Humans, Hydrocortisone, Male, Biomarkers, Outcome Assessment, Health Care, Hormone Replacement Therapy, Infusions, Subcutaneous, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.